TSC2 and tuberous sclerosis: Discussion: Our results suggest that methylation at TSC2 promoter is not likely to contribute to the variability of clinical manifestations observed in TSC patients; however, it would be important to analyse the most affected cells, like brain cells where TSC2 is highly expressed, and also other gene regulatory regions in order to better understand the pathophysiology of this genetic disease.